Tag Archives: amgn

Amgen, Xencor In $1.75 Billion Cancer Drug Alliance

Small biotech Xencor (XNCR) said Wednesday that it had entered a cancer-drug collaboration with Amgen (AMGN) that could be worth as much as $1.75 billion. Amgen agreed to pay $45 million upfront to license Xencor’s XmAb bispecific technology platform in five preclinical programs aimed at treating cancer as well as inflammatory diseases. If these succeed, Amgen will owe up to $1.7 billion in milestone payments. Bispecific antibodies are fragments

Amgen, Regeneron Upgraded On Cholesterol Drug Promise

Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) were both up Tuesday on upgrades from UBS after a survey suggested sales of their new cholesterol drugs could be even bigger than expected. Analyst Matthew Roden raised his rating on Regeneron all the way to buy from sell, and on Amgen to buy from neutral, after surveying 50 U.S. and European physicians about their attitudes toward the new PCSK9 inhibitors both companies have launched this summer.

Watch These 5 IBD 50 Drugmakers Amid Correction

The market is still in a correction, which means that it’s not the best time to buy; but it never hurts to keep an eye on some top performers, such as these hot drugmakers on the IBD 50. Valeant Pharmaceuticals (VRX) said at the start of the month that it will shell out $445 million in a psoriasis drug licensing deal with AstraZeneca (AZN). The drug candidate, brodalumab, may be effective, but AstraZeneca’s old partner Amgen (AMGN) nixed the